SchizophreniaArchives
The Economic Impact of Cumulative Metabolic Comorbidity Burden in Schizophrenia: A Claims-Based Analysis of Medical Costs in the United States
Schizophrenia 1 min.
Schizophrenia
1 min.
Published on 28/07/2026 |
Original article (Full-text)
| Han, Xue et al. | Neurology and Therapy. Volume 15(4).
Metabolic comorbidities, including central adiposity, dyslipidemia, insulin resistance, and hypertension, are common in individuals with schizophrenia and contribute to an increased risk of cardiovascular disease and related mortality. There is limited evidence quantifying the economic burden of metabolic...
Barriers to long-acting injectable antipsychotic use for community-dwelling patients with schizophrenia in China: a qualitative process analysis
Schizophrenia 1 min.
Schizophrenia
1 min.
Published on 21/07/2026 |
Original article (Full-text)
| Cui, Changjie et al. | BMC Psychiatry. Volume 26(1).
Long-acting injectable antipsychotics (LAIs) have proven more effective for treating patients with schizophrenia than oral formulations. However, the use of LAIs in China remains low and this phenomenon is still under-researched. This study endeavors to provide a better understanding by systematically...
